Libella Gene Therapeutics   Report issue

For profit Phase 1
Founded: Manhattan KS United States (2007)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2019
NCT04110964
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Libella Gene Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (1)

aav-htert (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Ischemia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 1